

Subject index

t(X:17) renal carcinoma, 37
34bE12, cytokeratin, 24, 27, 34, 40,
172, 173, 174, 201, 206
3p deletions, 24, 25

A

Acetylator genotypes, 13
Acinar adenocarcinoma, 162, 175, 177,
199, 200, 201
Acrorchordon, 20
Adenomatoid tumour, 218, 267, 268,
269
Adenomyoma, 214
Adenosquamous carcinoma, 160, 205,
281, 284, 287, 288
Adrenogenital syndrome, 251, 252
Adult mesoblastic nephroma, 77
Adult type granulosa cell tumour, 218,
257
AE1/AE3, cytokeratin, 24, 27, 36, 80,
101, 102, 138, 152, 233, 268, 269,
271, 272
AFP, See Alpha fetoprotein
Aggressive angiomyxoma, 276
AKT, 61
Albumin, 241
Alpha fetoprotein, 220, 221, 224, 232,
235, 236, 238, 240-242, 244, 247-
249, 255, 272
Alpha-2-globulin, 13
Alpha-methyl-CoA racemase, 174
AML, 65-69
Amyloidosis, 13
Analgesics, 13, 94, 151
Androblastoma, 253
Androgen insensitivity syndrome, 251,
254
Androgen receptor, 164, 172, 174, 186
Angiodysplasia, 45-47
Angiogenesis, 15, 17, 109
Angiokeratoma, 293-295
Angiolymphoid hyperplasia with
eosinophilia, 295
Angioma, 51
Angiomyofibroblastoma, 274-276

Angiomyolipoma, 10, 14, 52, 63, 65-68,
70
Angiosarcoma, 10, 64, 71, 90, 102, 141,
146, 153, 160, 178, 210, 211, 215,
293, 294, 296, 297
Angiotensin 1-converting enzyme, 233
Aniridia, 48, 51
Anthracyclines, 105
Antihypertensive drugs, 13
Antoni A pattern, 75
Antoni B pattern, 75, 295
APC, 225
Arsenic, 12, 94
Asbestos, 12, 269
ASPL, 37, 38
ASPL-TFE3 carcinomas, 37
ASPSCR1, 37
Atrophic variant, 175
Atypical adenomatous hyperplasia, 171,
173, 174
Atypical lentiginous hyperplasia, 292
Atypical melanocytic nevi of the
acral/genital type, 292
Atypical neurofibromas, 145
Azzopardi phenomenon, 82, 135

B

Balkan nephropathy, 151
Basal cell adenoma, 160
Basal cell carcinoma, 160, 206, 281,
288
Basal cell hyperplasia, 172, 206
Basaloid carcinoma, 281, 284, 286
B-cell acute lymphoblastic leukaemia,
60
B-cell lymphoma, 85, 147, 264
BCL10, 225
BCL2, 57, 79, 192, 197, 206, 265
Beckwith-Wiedemann syndrome, 51, 52
Bellini duct carcinoma, 33
Benign mesothelioma, 218, 268, 270
bFGF, 25
BHD, 15, 18, 20, 21
BHD syndrome, 20

Bilateral papillary renal cell tumours, 17
Birth weight, 13, 223
Birt-Hogg-Dubé syndrome, 20, 21
Bizarre leiomyoma, 211
Blastemal cells, 48-52, 54
Bloom syndrome, 51
Body mass index (BMI), 12
Bone metastases, 13, 57, 96, 166, 177,
205
Bone metastasizing renal tumour of
childhood, 56
Bowen disease, 281, 289-291
Bowenoid papulosis, 289, 290
Brenner tumour, 218, 263
Broad ligament cystadenoma, 15, 16
Brunn nests, 99, 114, 120
Burkitt lymphoma, 147
Burned out germ cell tumour, 248
Buschke-Löwenstein tumour, 289

C

CA125, 100, 133, 213, 214
Cadmium, 12
Calcifications, 254, 260, 262
Calcifying fibrous (pseudo) tumour, 274,
276
Call-Exner bodies, 257, 258
Calponin, 66, 295
CAM 5.2, 24, 27, 36, 40, 80, 233, 272
Carcinoembryonic antigen, 27, 36, 100,
133, 214, 235, 238, 245, 247, 256,
268, 270, 271, 288, 291
Carcinoid, 10, 81, 84, 90, 99, 135, 138,
153, 160, 207, 218, 245, 246, 262,
279
Carcinoma associated with neuroblas-
toma, 10, 39
Carcinoma of Skene, Cowper and Littré
glands, 90
Carcinoma of the collecting ducts of
Bellini, 10, 33, 34
Carcinosarcoma, 63, 102, 160, 178
Carney syndrome, 253, 255
Caruncle, 147, 157
CCNA, 226

CCNB, 226
CCND1, 105, 108
CCND2, 226, 227
CCNE, 226
CCRCC, 15, 16
CCSK, 56, 57
CD10, 24, 31, 34, 37, 40, 265
CD117, 84, 230, 232-235
CD143, 233
CD15, 34, 40
CD30, 232-235, 238, 249, 298
CD31, 62, 64, 141, 296
CD34, 45, 47, 57, 60, 62, 64, 73, 75, 109, 141, 209, 268, 276, 295, 296
CD44, 117, 192
CD56, 82, 85, 264
CD57, 45
CD63, 66
CD68, 66, 143
CD99, 57, 62, 75, 79, 80, 84, 258
CDC, 34
CDK4, 105, 108
CDKN1A, 225
CDKN1B, 225
CDKN2A, 107, 121, 225
CDKN2B, 107, 121, 225
CDKN2C, 225
CDKN2D, 225
CEA, See Carcinoembryonic antigen
Cellular angiofibroma, 275, 276
Cellular congenital mesoblastic nephroma, 60
Cellular neurofibromas, 145
Cerebral gigantism, 51
Charcot-Böttcher crystals, 255
Chondroma, 160, 209
Chondrosarcoma, 102, 103, 144, 160, 178, 209, 211, 236, 247
Choriocarcinoma, 10, 153, 160, 215, 218, 221, 224, 233, 238, 241-244, 247-249
Chromogranin A, 82, 84, 85, 135-138, 192, 196, 207, 247, 262
Chromophobe renal cell carcinoma, 10, 30-32
Chronic cystitis, 94, 147
Chronic prostatitis, 184
CK14, 24
CK18, 24, 40
CK19, 24, 34, 40
CK20, 101, 133, 204
CK7, 40, 133, 204
CK8, 24, 101, 233

C-KIT, 226, 232, 233
Clear cell adenocarcinoma, 133, 213
Clear cell carcinoma, 25, 281, 285, 287
Clear cell renal carcinoma, 10, 15, 16, 21, 23-25, 34, 66, 133
Clear cell sarcoma, 10, 52, 56, 57, 293, 296, 297
Clear cell sarcoma of the kidney, 56
Clear cell variant of urothelial carcinoma, 103
Cloacogenic carcinoma, 172
Clusterin, 123
C-MYC, 197
Coagulopathy, 13
Collecting duct carcinoma, 33, 34, 36
Collective duct carcinoma, 18
Colloid and signet ring variant, prostate adenocarcinoma, 176
Comedonecrosis, 181
Condyloma acuminatum, 127, 157
Congenital mesoblastic nephroma, 10, 60, 61
Cowper glands, 90, 155, 172
COX-2, 109
Cribriform pattern, 180, 199, 201
Cryptorchidism, 223, 229, 235, 251
Cul-2, 17
Cutaneous leiomyomas, 18, 19
Cutaneous nevi, 51
Cyclin-dependent kinase inhibitor, 17
Cyclooxygenase, 109
Cyclophosphamide, 94, 102, 140
Cystadenocarcinoma, 262
Cystadenoma, 160, 213, 214, 218, 262, 266, 271, 272
Cystic hamartoma of renal pelvis, 77
Cystic mesothelioma, 218
Cystic nephroma, 10, 55, 76
Cystic nodular hyperplasia of the prostate, 213
Cystic partially differentiated nephroblastoma, 10, 48, 55
Cystic trophoblastic tumour, 243
Cystitis cystica, 99, 120, 132, 147
Cystitis glandularis, 99, 130, 132, 147
Cytokeratin 20, 111-113, 117, 118, 120, 123, 134, 214
Cytokeratin 7, 18, 45, 104, 114, 134, 214

D

DBCCR1, 121

DCC, 225
Dedifferentiated liposarcomas, 275
Denuding cystitis, 119
Denys-Drash syndrome, 51
Dermatofibrosarcoma protuberans, 293, 296, 297
Dermoid cyst, 218, 244, 245, 247
Desmoplastic small round cell tumour, 218, 272, 274
Desmoplastic stromal response, 97, 175, 202
Diethylstilboestrol, 12, 223
Ductal adenocarcinoma, 199, 200, 201

E

EBV, See Epstein-Barr virus
E-cadherin, 25, 123, 187, 192
EGFR, See Epidermal growth factor receptor
Elongin, 17
Embryonal carcinoma, 160, 218, 221, 224, 227, 233, 234, 236-240, 244, 247-250
Embryonal rhabdomyosarcoma, 139, 211, 277
Endodermal sinus tumour, 238, 240, 241
Endolymphatic sac tumours, 15, 16
Endometriosis, 130, 133, 134, 146
Ependymoblastoma, 247
Epidermal growth factor receptor, 25, 105, 107, 108, 109, 122, 126
Epidermoid cyst, 244, 245, 247
Epididymal cystadenomas, 16
Epigenetic silencing, 24
Epithelial membrane antigen, 24, 26, 34, 40, 45, 57, 80, 104, 134, 238, 243, 256, 271
Epithelioid angiomyolipoma, 10, 68
Epithelioid angiosarcoma, 141
Epithelioid haemangioendothelioma, 293, 294, 297
Epithelioid sarcoma, 293-297
Epithelioid/pleomorphic angiomyolipoma, 64
EPO, See Erythropoietin
Epstein-Barr virus, 85, 101, 147, 178, 264, 265
Erythrocytosis, 13, 17
Erythroplasia of Queyrat, 281, 289
Erythropoietin, 13, 17, 48
Estrogen, 13, 66, 77, 78, 133, 154, 210, 223, 251, 276

ETV6, 60
Ewing sarcoma, 83, 84, 153, 257, 274,
293, 297
EWS-WT1, 274
Extrophy, 129, 130

F

Factor VIII, 64, 71, 109, 268
Familial renal cell carcinoma, 15
FAS, 197, 226
FGFR3, 113, 120, 122, 123
FH, 15, 18-20
FHIT, 225
Fibroadenoma, 214
Fibroepithelial polyps, 153, 156
Fibrofolliculoma, 15, 20
Fibroma, 209, 218, 258
Fibromatosis, 57, 60, 61
Fibronectin, 17
Fibrosarcoma, 60, 61, 153, 258, 276,
277, 287, 296
Fibrous hamartoma of infancy, 274, 276
Fibrous histiocytoma, 143, 153, 211,
215, 247, 269, 287, 293, 294
"Field defect" hypothesis, 121
Florid basal cell hyperplasia, 206
Foamy gland variant, 175
Foamy variant, PIN, 196
Frasier syndrome, 51
Fuhrman system, 27
Fungal toxins, 12

G

Genital lentiginosis, 292
Genitourinary malformation, 51
Gnomic imprinting, 52, 225
Germ cell tumours, 10, 87, 160, 213,
217, 218, 221, 226, 227
Germ cell-sex cord/gonadal stromal
tumour, unclassified, 218, 261
GFAP, 47, 247
Giant cell fibroblastoma, 293, 294, 297
Giant condyloma, 289
Giant multilocular prostatic cystadenoma,
213
Gleason grading, 169, 170, 179-183
Gleason pattern, 180-185, 200
Glomus tumour, 293, 294, 297
Glutathione S-transferase M1, 94

Glutathione S-transferase M1 null genotype,
13
Gonadoblastoma, 218, 260, 261
Gonadotropin, 14, 103, 224, 236, 242,
255
Gonadotropin, human chorionic, 220,
224, 233, 235, 242-249
Granular cell renal cell carcinoma, 23
Granular cell tumour, 145, 160, 209,
211, 274, 293-297
Granulosa cell tumour, 218, 251, 256-
259
Grawitz tumour, 23
GSTP1, 197
Gynecomastia, 13, 14, 224, 242, 251,
255-259

H

H19, 123
Haemangioblastoma, 15-17, 272
Haemangioma, 10, 71, 90, 141, 146,
153, 157, 160, 209, 293-297
Haemangiopericytoma, 10, 62, 75, 79,
144, 160, 215
Haemangiosarcoma, 64
Haematopoietic and lymphoid tumours,
10, 90
Hamartin, 67
hCG, See Gonadotropin, human chorionic
Hemihypertrophy, 51, 52
Hepatocyte growth factor, 17, 18
Hepatosplenomegaly, 13
HER2, 25, 34, 105, 106, 108, 109, 122,
126
Herceptin, 105
Hereditary leiomyomatosis, 18
Hereditary leiomyomatosis and renal
cell cancer syndrome, 18-20
Hereditary nonpolyposis colon cancer,
103, 152
Hereditary papillary renal carcinoma,
17, 18
Hibernoma, 153
HIF-1, 17
High grade intraepithelial neoplasia,
119
HLRCC, See Hereditary leiomyomatosis
and renal cell cancer syndrome
HMB45, 66, 68-70, 146, 273, 279
HMB50, 66
Hodgkin lymphoma, 12, 84, 85, 147,
157, 212, 298

Homer Wright rosettes, 84
Horseshoe kidney, 81
HPC2/ELAC2, 184, 186
HPV, 127, 154, 155, 228, 283, 284, 286-
291
HRAS, 105, 126
hSNF5, 59
hSNF5/INI1, 59
Human glandular kallikrein 2, 167
Hydronephrosis, 85, 95, 147, 152
Hypercalcemia, 13, 85, 135
Hypernephroma, 23
Hyperreninism, 47
Hypertension, 13, 46-48, 62, 72, 73, 85,
137, 214
Hypoglycemia, 62, 215
Hypospadias, 223, 257
Hypoxia-inducible factor (HIF) 1, 17

I

IGF2, 61
IL-8, 25
Immature teratoma, 244
Immunosuppression, 85
Infantile fibromatosis, 60
Infantile fibrosarcoma, 60
Infiltrating urothelial carcinoma, 90, 93,
97, 98, 102, 103
Infiltrating urothelial carcinoma with
glandular differentiation, 98
Infiltrating urothelial carcinoma with
squamous differentiation, 97
Inflammatory pseudotumour, 102, 140,
145, 157
Inherited cancer syndromes, 9, 15
Inhibin, 232, 243, 251, 252, 254, 256,
257, 260, 261
INI1, 59
Insulin-like growth factor (IGF)-2, 61
Insulin-like growth factor 1 receptor, 61
Interstitial cell tumour, 251
Intestinal metaplasia of the urothelium,
129
Intralobar nephrogenic rests, 54
Intratubular germ cell neoplasia, unclassified,
223
Inverted papilloma, 99, 114, 115, 138,
153, 156
Inverted urothelial papilloma, 90
Inverted variant, PIN, 196
IGCNU, 223, 225, 228-231, 234, 244

- J**
- Juvenile type granulosa cell tumour, 218, 257
 - Juvenile xanthogranuloma, 293, 297
 - Juxtaglomerular cell hyperplasia, 46, 47
 - Juxtaglomerular cell tumour, 10, 72, 73
- K**
- KALK13, 225
 - Kaposi sarcoma, 141, 144, 146, 267, 275, 282, 293, 294, 296, 297
 - Ki-67 antigen, 113, 123, 130, 192, 206
 - Kidney cysts, 15, 16
 - Klinefelter syndrome, 251
 - Klipel-Trenaunay-Weber syndrome, 146
 - Klippel-Trenaunay syndrome, 51, 71
 - KRAS2, 226, 227
- L**
- Lactate dehydrogenase, 220, 224
 - Large cell calcifying Sertoli cell tumour, 218, 253, 255
 - Large cell undifferentiated carcinoma, 103
 - LDH, See Lactate dehydrogenase
 - Lectin, 34
 - Leiomyoma, 10, 70, 144, 211, 215, 276, 293, 294
 - Leiomyomas of the skin and uterus, 18
 - Leiomyosarcoma, 19, 63, 140, 210, 215, 275, 294, 296
 - Leiomyosarcoma of the uterus, 19
 - Leu M1, 100, 268, 270, 271
 - Leukaemia, 10, 87, 160
 - Leydig cell tumour, 218, 251-253, 256, 258, 259
 - Lichen sclerosus, 282, 289, 290
 - Lipid-cell variant, urothelial carcinoma, 103
 - Lipoma, 21, 153, 274, 276
 - Liposarcoma, 64, 66, 102, 103, 144, 160, 178, 215, 274-276
 - Littre glands, 90, 155
 - Low grade papillary urothelial carcinoma, 104, 113
 - Lymphangioliomyomatosis (LAM), 65
 - Lymphangioma, 10, 71, 270, 293, 294, 297
 - Lymphangioma circumscriptum, 295
 - Lymphoepithelioma-like carcinoma, 100, 101, 103, 108, 135
 - Lymphoepithelioma-like variant, 177
 - Lymphoma-like variant, urothelial carcinoma, 101
 - Lynch syndrome, 152
- M**
- Macroglossia, 52
 - MAK6, 40
 - Malakoplakia, 172, 252
 - Maldescended testes, 223
 - Male adnexal tumour of probable Wolffian origin, 160
 - Male angiomyofibroblastoma-like tumour, 275
 - Male infertility, 223
 - Malignant epithelial-stromal tumour, 214
 - Malignant fibrous histiocytoma, 10, 64, 90, 143, 160, 209, 215, 275-277, 293-297
 - Malignant Leydig cell tumour, 252
 - Malignant lymphoma, 101, 135, 147, 221
 - Malignant melanoma, 90, 146, 157, 213, 292
 - Malignant mesothelioma, 218, 268-270
 - Malignant peripheral nerve sheath tumour, 144, 145, 160, 247, 293, 297
 - Malignant Sertoli cell tumour, 218, 256
 - Malignant teratoma, undifferentiated, 237
 - MALT lymphoma, 147, 265
 - MAP kinase, 61
 - Mart1/Melan A, 66
 - Mature teratoma, 218, 244, 245
 - MDM2, 105, 108, 136, 226, 241
 - Medulloepithelioma, 247
 - Melanocytic markers, 66, 69
 - Melanocytic nevus, 90, 281, 292
 - Melanotic hamartoma, 272
 - Melanotic neuroectodermal tumour, 218, 272, 273
 - Melanotic progonoma, 272
 - Merkel cell carcinoma, 281, 288
 - Merkel cell tumour, 279
 - Mesangial sclerosis, 51
 - Mesoblastic nephroma, 52
 - Mesonephric carcinoma, 133
 - MET, 15, 18, 108, 188
 - Metalloproteinase 2, 17
 - Metalloproteinase 2 (TIMP-2), 17
 - Metanephric adenofibroma, 10, 44-46
 - Metanephric adenoma, 10, 44-46
 - Metanephric adenocarcinoma, 44
 - Metanephric stromal tumour, 10, 46, 47
 - MFH, See Malignant fibrous histiocytoma
 - MHC class II, 25
 - MIB-1, 133, 145, 252
 - MIC2 (CD99), 57
 - Michaelis Gutman bodies, 252
 - Microphthalmia transcription factor, 66
 - Micropapillary carcinoma, 100
 - Micturition attacks, 137, 214
 - Mixed embryonal carcinoma and teratoma, 218
 - Mixed epithelial and stromal tumour, 10, 77, 78
 - Mixed gonadal dysgenesis, 257, 260
 - Mixed mesenchymal and epithelial tumours, 10
 - Mixed teratoma and seminoma, 218
 - MLH1, 152
 - MMP-2, 25
 - MMP-9, 25
 - Monodermal teratoma, 218, 244-246
 - Monophasic choriocarcinoma, 218, 241, 243
 - Monosomy X, 71
 - MSH2, 152
 - MSH3, 152
 - MSH6, 152
 - MSR1, 184, 186
 - MST, 46, 47
 - MUC3, 24
 - MUC5AC, 98
 - MUC1, 24
 - Mucinous (colloid) adenocarcinoma, 176
 - Mucinous borderline tumours, 262
 - Mucinous carcinomas, 132
 - Mucinous cystadenocarcinoma, 218
 - Mucinous cystadenoma, 218
 - Mucinous tubular and spindle cell carcinoma, 10, 40
 - Mucinous variant, PIN, 196
 - Mucosal papules, 21
 - Multifocal bladder neoplasms, 121
 - Multilocular clear cell renal cell carcinoma, 10
 - Multilocular cyst, 213
 - Multilocular cystic renal cell carcinoma, 26

Multiple leiomyomas of the skin, 18
Multiple renal tumours, 20
MYBL2, 108, 226
MYCL1, 226
MYCN, 226
Myf4, 277
MyoD1, 139, 276, 277
Myointimoma, 293-297
Myxofibrosarcoma, 293, 297
Myxoid chondrosarcoma, 37
Myxoma, 57

N

N-acetyltransferase 2, 13
Nelson syndrome, 252
Neonatal jaundice, 223
Nephroblastic tumours, 10
Nephroblastoma, 12, 48-56, 87, 213, 218, 247, 263, 279
Nephroblastomatosis, 53, 54
Nephrogenic adenoma, 78, 99, 133, 156, 172
Nephrogenic metaplasia, 99
Nephrogenic rests, 10, 53
Nested variant of urothelial carcinoma, 99, 138
Neuroblastoma, 10, 39, 52, 84, 160, 213, 214, 247, 279
Neuroendocrine carcinoma, 10, 82, 135, 136, 248
Neuroendocrine tumours, 10, 16, 90, 153, 160, 172, 207
Neurofibroma, 145, 153, 258, 274, 293-297
Neurofibromatosis, 51
Neurofibromatosis type 1, 145
Neuron specific enolase, 51, 66, 84, 138, 207, 273
NF2, 296
Nodular mesothelial hyperplasia, 270
Non-invasive papillary urothelial carcinoma, high grade, 90, 117
Non-invasive papillary urothelial carcinoma, low grade, 90, 104, 116
Non-invasive papillary urothelial neoplasm of low malignant potential, 90
Non-invasive urothelial neoplasia, 123
Non-invasive urothelial tumours, 110
Non-keratinizing squamous metaplasia, 114
NonO (p54NRB), 37
Normal urothelium, 112

Normocytic anaemia, 13
NRC-1, 25
NSE, 84, 274
NTRK3, 60
Nuclear grooves, 41, 258

O

Obesity, 9, 13, 95, 164
Omphalocele, 52
Oncocyte, 42
Oncocytic tumour, 18, 21
Oncocytic variant, prostate carcinoma, 177
Oncocytoma, 10, 15, 39, 42, 43, 65, 66
Oncocytomatosis, 43
Oncocytosis, 43
Orchioblastoma, 238
ORTI, 62
Osseous metaplasia, 26, 44, 142
Ossifying renal tumour of infancy, 62
Ossifying renal tumour of infants, 10
Osteosarcoma, 63, 90, 102, 103, 142, 144, 153, 178, 209, 211, 247, 293, 297
Overweight, 12

P

p14ARF, 121, 123
p15, 103, 107, 108, 121, 228
p16, 21, 107, 121, 130
p27, 17, 109, 122, 186, 187, 197
p63, 117, 118, 123, 174
Paget disease, 172, 281, 282, 285, 290, 291
PAP, See Prostatic acid phosphatase
Papillary adenoma, 10, 41
Papillary carcinoma, 28, 281, 284, 287
Papillary necrosis, 151
Papillary renal adenomas, 41
Papillary renal cell carcinoma, 10, 15, 18, 27-29
Papillary serous carcinoma of the ovary, 100
Papillary urothelial neoplasm of low malignant potential, 104, 115, 116
Paraganglioma, 85, 90, 99, 136-138, 160, 213, 218, 263
Paraneoplastic endocrine syndromes, 13
Paratesticular liposarcoma, 275, 276
Paratesticular rhabdomyosarcoma, 275, 277
Parity, 13
Penile melanosis, 292
Perilobar nephrogenic rest, 53
Peripheral neuroectodermal tumour, 52
Peripheral neuroepithelioma, 247
Peritumoural fibrous pseudocapsule, 49, 53, 54
Perlman syndrome, 51
Pesticides, 12
Peutz-Jeghers syndrome, 253-255
Peyrone disease, 298
Pheochromocytoma, 10, 15, 17, 85, 136, 153, 214
Phenacetin, 13, 94, 151
Phosphatidylinositol-3-kinase (PI3K), 61
PI3/Akt, 186
PIN, See Prostatic intraepithelial neoplasia
Placental alkaline phosphatase, 100, 229-238, 243, 245, 247, 249, 255, 256, 260, 261
Placental site trophoblastic tumour, 218, 243
PLAP, See Placental alkaline phosphatase
Plasmacytoid carcinoma, 135
Plasmacytoid variant, urothelial carcinoma, 101
Plasmacytoma, 10, 86, 90, 101, 102, 147, 153, 157, 264, 265
Platelet-derived growth factor beta, 17
Pleuropulmonary blastoma, 76
PNET, 58, 59, 83, 84, 245-248, 279
Pneumothorax, 15, 20
Polycyclic aromatic hydrocarbons, 13
Polycythemia, 44, 48
Polyembryoma, 221, 247, 248, 250
Polyvesicular vitelline, 240, 242
Post-atrophic hyperplasia, prostate, 173, 175
Postoperative spindle cell nodule/tumour, 140, 145
Posttransplant lymphoproliferative disease, 147
PRCC, 15, 27, 28, 37
PRCC-TFE3 renal carcinomas, 37
Priapism, 298, 299
Primitive neuroectodermal tumour, 10, 83, 245, 246
Prolactin, 14
Promontory sign, 296

Promoter methylation, 21
 Prostate specific antigen, 154, 159, 161, 163-169, 172, 174, 177-179, 188-190, 192, 194, 198, 199, 201-208, 212-214, 278
 Prostate specific membrane antigen, 167, 172
 Prostatic acid phosphatase, 81, 167, 172, 177, 178, 201, 204, 205, 208, 214
 Prostatic intraepithelial neoplasia, 160, 174, 180, 186-188, 193-198
 Protein degradation, 17
 PSA, See Prostate specific antigen
 Psammoma bodies, 37, 41, 44, 45, 100, 252
 Pseudoglandular spaces, 98
 Pseudohermaphroditism, 51
 Pseudohyperparathyroidism, 13
 Pseudohyperplastic prostate cancer, 175
 Pseudosarcomatous stromal reaction, 97
 PTEN, 25, 32, 107, 185, 187
 Pulmonary cysts, 20, 21
 PUNLMP, 110, 113, 115-117, 122
 Purkinje cells, 16
 Pushing margin, 23
 pVHL, 15, 16, 17
 Pyogenic granuloma, 141

R

Ras, 61, 122
 RASSF1A, 25
 RB1, 107
 Rbx1, 17
 RCC17, 37
 Reactive atypia, 112
 Reinke crystals, 251, 252
 Renal adenomatosis, 41
 Renal angiosarcoma, 64
 Renal carcinoid tumour, 81
 Renal carcinoma, 30, 52
 Renal cell cancer, 12-31, 38, 39, 65, 299
 Renal cell carcinoma, 14-34, 39, 41, 43, 65, 68, 75, 212, 279, 299
 Renal Cell Carcinoma Marker antigen, 37
 Renal cell carcinoma, unclassified, 10, 43
 Renal failure, 67, 85, 147

Renal medullary carcinoma, 10, 35
 Renal oncocytoma, 20, 42
 Renal osteosarcoma, 63
 Renin, 13, 48, 67, 72, 73
 Renomedullary interstitial cell tumour, 10, 74
 Retained placenta, 223
 Rete adenomas, 256
 Rete testis carcinoma, 266
 Retina, 15, 16
 Retinal anlage tumour, 272
 Retinoblastoma, 107, 109, 122
 Retrograde metastasis, 23
 Rhabdoid cells, 79
 Rhabdoid tumour, 10, 52, 58, 59, 160, 213
 Rhabdoid tumour of the kidney (RTK), 58
 Rhabdomyosarcoma, 102, 139, 145, 153, 160, 178, 209-211, 236, 248, 270, 274-277, 293, 296, 297
 RNASEL, 184, 186
 RTK, 58, 59

S

S. haematobium, 124, 125, 130
 S100 protein, 27, 47, 57, 66, 84, 137, 145, 146, 206, 247, 252, 254, 256-259, 271, 273, 295
 Sarcomatoid carcinoma, 64, 102, 108, 140, 142, 144, 153, 155, 157, 160, 178, 179, 236, 287, 288
 Sarcomatoid change, 23, 43
 Sarcomatoid variant, urothelial carcinoma, 102
 Schiller-Duval bodies, 240
 Schistosoma haematobium, 94, 124, 125, 130
 Schistosoma japonicum, 124
 Schistosoma mansoni, 124
 Schistosomiasis, 124-127, 130, 142, 147, 205
 Schwannoma, 56, 75, 153, 274, 293, 294, 295, 297
 Sclerosing adenosis, 173
 Sclerosing Sertoli cell tumour, 218, 253, 255
 Sebaceous carcinoma, 281, 288
 Seminoma, 160, 221-240, 244-249, 255, 256, 260
 Seminoma with syncytiotrophoblastic cells, 218, 233
 Serotonin, 138, 207
 Serous carcinoma, 218
 Serous tumour of borderline malignancy, 218
 Sertoli cell tumour, 218, 232, 238, 253-256, 258, 266
 Sertoli cell tumour, lipid rich variant, 218
 Serum alkaline phosphatase, 13
 Sick cell trait, 35
 Signet-ring variant, 195
 Simpson-Golabi-Behmel syndrome, 51
 SIOP, 48, 49, 52
 Skene glands, 90, 155
 SMAD4, 225
 Small cell carcinoma, 90, 135, 136, 153, 160, 207, 208, 281, 288
 Small cell neuroendocrine carcinoma, 207
 Small cell neuroendocrine variant, PIN, 196
 Smooth muscle actin, 66, 69, 102, 144, 206, 257, 258, 259, 295, 296
 Soft tissue alveolar soft part sarcoma, 37
 Solitary fibrous tumour, 10, 75, 144, 160, 209, 211, 215, 258
 Sotos syndrome, 51
 Soya bean agglutinins, 40
 Spermatocytic seminoma, 218, 221, 223-225, 229, 234-237
 Spermatocytic seminoma with sarcoma, 218, 236, 237
 Spermatogenesis, 230
 Spermatogenic arrest, 231
 Spermatogonia, 223, 230, 231
 Spindle cell rhabdomyosarcoma, 275, 277
 Squamous cell carcinoma, 90, 124-127, 153-156, 160, 205, 281-290
 Squamous cell papilloma, 90, 127
 SRD5A2, 164
 SSX family gene, 80
 Steroid 5-alpha reductase type II, 164
 Stromal proliferations of uncertain malignant potential of the prostate, 209
 Stromal sarcoma, 160, 209
 Stromal tumour of uncertain malignant potential, 160, 209
 STUMP, 209, 210
 Sturge-Weber syndrome, 71, 146
 Sustentacular cells, 85, 136, 137
 Synaptophysin, 81, 82, 84, 85, 137, 138, 196, 207, 247, 273
 Syncytiotrophoblastic cells, 103, 238, 243, 244, 249

Synovial sarcoma, 10, 52, 79, 80, 209, 211, 236, 293, 296, 297
Systemic angiomatosis, 71
SYT gene, 80
SYT-SSX gene fusion, 80

T

TCL1, 226
Teratoma, 87, 160, 172, 218, 221, 223, 224, 227, 229, 236-238, 244-250, 262
Teratoma differentiated, 244
Teratoma differentiated (immature), 244
Tertiary Gleason patterns, 181
Testisin, 225
TFE3, 37, 38
TFE3 fusion proteins, 37
Thecoma, 218, 258
Thorium, 151
Thyroid transcription factor-1, 208
TIMP-2, 17
Tobacco, 9, 13, 89, 93, 151
Tobacco smoking, 12, 93, 124, 151
TOP2A, 105, 108, 109
TP53, 32, 69, 109, 120, 122, 126, 228
Transforming growth factor (TGF-alpha), 17
Transitional cell carcinoma, 93
Translocation, 21
Trichodiscomas, 20
TSC1, 15, 67, 121, 122
TSC2, 15, 67
TTF-1, 208
Tuberin, 67
Tuberous sclerosis (TS), 65

U

Ubiquitin, 17
Ulex europaeus, 34, 40, 71
Unclassified spindle cell (sarcomatoid) carcinomas, 40
Undifferentiated carcinoma, 103
Undifferentiated high grade pleomorphic sarcoma, 143
Urachal adenocarcinomas, 130, 132
Urachal carcinoma, 131
Urachus, 131, 132, 134
Urothelial atypia of unknown significance, 112

Urothelial carcinoma, 90, 92, 97, 99, 100, 102-104, 119, 120, 156, 160, 202-204
Urothelial carcinoma in situ, 90, 119, 120, 204
Urothelial carcinoma with giant cells, 102
Urothelial carcinoma with trophoblastic differentiation, 103, 104
Urothelial dysplasia, 111
Urothelial hyperplasia, 111
Urothelial papilloma, 90, 113, 122, 153
Uterine leiomyomas, 15, 19
Uterine leiomyosarcoma, 18-20
Uterus papillary type 2 renal cancer, 18

V

Vascular endothelial growth factor, 17, 25, 207
VEGF, See Vascular endothelial growth factor
Verocay bodies, 75, 295
Verrucous carcinoma, 90, 92, 127, 155, 281, 284, 287-290
VHL, 15-17, 22, 24, 25
VHL type 1, 17
VHL type 2, 17
Villin, 129
Villous adenoma, 90, 134, 153, 154
Visceromegaly, 52
von Hippel Lindau, 24, 71
von Hippel-Lindau disease, 9, 15-17, 23, 24, 271, 272

W

Wagner-Meissner-like bodies, 295
WAGR syndrome, 51
Warty (condylomatous) carcinoma, 281, 286, 287
Well differentiated endometrioid carcinoma, 218
Well differentiated papillary mesothelioma, 218, 270
Wilms tumour, 44, 48, 51, 55-57, 62, 84, 153, 160, 213, 260
Wilms-Aniridia-Genital anomaly-Retardation (WAGR) syndrome, 51
WT1, 45, 51, 52, 62, 84, 225, 260, 274
WT2, 52, 62

X

Xeroderma pigmentosum, 236
Xp11 translocation carcinomas, 10, 38
Xp11.2 translocations, 37
Xp11.2-associated carcinomas, 37

Y

Yolk sac tumour, 160, 218, 221, 223, 224, 227, 229, 238, 240-242, 244, 248-250, 256, 258

Z

Zellballen pattern, 85, 137